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Prostate cancer (PCA) still represents a leading cause of death. An increasing number of
studies have documented that microRNAs (miRNAs), a subgroup of non-coding RNAs with
gene regulatory functions, are differentially expressed in PCA respect to the normal tissue
counterpart, suggesting their involvement in prostate carcinogenesis and dissemination.
Interestingly, it has been shown that miRNAs undergo the same regulatory mechanisms
than any other protein coding gene, including epigenetic regulation. In turn, miRNAs can
also affect the expression of oncogenes and tumor suppressor genes by targeting effec-
tors of the epigenetic machinery, therefore indirectly affecting the epigenetic controls on
these genes. Among the genes that undergo this complex regulation, there is the androgen
receptor (AR), a key therapeutic target for PCA.This review will focus on the role of epige-
netically regulated and epigenetically regulating miRNAs in PCA and on the ﬁne regulation
of AR expression, as mediated by this miRNA–epigenetics interaction.
Keywords: microRNA, prostate cancer, epigenetics, androgen receptor, methylation, histone acetylation
INTRODUCTION
Epigenetics is the study of changes in gene expression caused by
mechanisms other than changes in the DNA sequence. Accumula-
tion of genetic and epigenetic alterations is one of the most impor-
tant factors in the tumorigenesis and progression of prostate can-
cer (PCA). DNA hypermethylation, loss of imprinting and altered
histone modiﬁcation patterns have been frequently reported in
PCA. The transcriptional control of gene expression is regulated
by a complex machinery composed of DNA methyltransferases
(DNMTs), histone acetyltransferases (HATs), histone deacetylases
(HDACs), histone methyltransferases (HMTs), histone demethy-
lases (HDMTs), and chromatin remodeling enzymes.
Hypermethylation of a 5′-cytosine to guanosine in CpG rich
areas located in the promoter region of several genes occurs fre-
quently in PCA, but rarely in normal prostate tissue, resulting in
silencing of methylated genes. Many of these epigenetically regu-
lated genes are tumor suppressor genes (TSGs), whose silencing
promotes a carcinogenetic effect. In addition to this mechanism,
also upregulation of effectors of the epigenetic machinery, such as
the HMT enhancer of zeste homolog 2 (EZH2) has been associ-
ated with high proliferation rate and aggressive tumor subgroups
in PCA. These data highlight the importance of epigenetic factors
in PCA genesis and progression.
MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs)
with gene regulatory functions (Ambros, 2001). The advent of
high throughput techniques has revealed that aberrations of the
miRNome (deﬁned as the full spectrum of miRNA expression in
a given genome) occur in almost all human tumors, with respect
to the normal tissue counterpart, including PCA (Volinia et al.,
2006; Dillhoff et al., 2008; Croce, 2009; Fabbri and Croce, 2011).
In addition to the “traditional” mechanism of action of miRNAs
(according to which these ncRNAs mainly silence the target gene
by binding to the 3′-untranslated region, 3′-UTR of its mRNA;
Bartel, 2004), miRNAs can also increase the translation of their
target gene, by binding to the 5′-UTR of the targeted mRNA
(Vasudevan et al., 2007), and it has also been observed that they can
affect gene expression by modifying their epigenetic control (Fab-
bri et al., 2007a). In particular, our group was able to show that in
cancer, a speciﬁc family of miRNAs (namely, the miR-29 family)
directly targets DNMT3A and DNMT3B (Fabbri et al., 2007a),
and indirectly targets DNMT1 (Garzon et al., 2009), leading to
a global reduction in cancer cell methylation and re-expression
of TSGs (such as WWOX and FHIT), normally epigenetically
silenced in tumors, and to an anti-tumoral effect. Moreover, sev-
eral groups have previously shown that miRNAs undergo the
same epigenetic regulatory mechanisms that affect the expres-
sion of any other protein coding gene (PCG), revealing a complex
level of interaction between epigenetics and miRNAs. This review
will focus on the implications of this miRNA–epigenetics net-
work for PCA, and will provide the state-of-the-art knowledge
on how the intertwined relationship between miRNA and epi-
genetics regulates the expression of the androgen receptor (AR),
one of the main actors in the development and progression of
PCA, therefore providing the rationale for new possible therapeu-
tic avenues for the treatment of this still very debilitating type of
cancer.
miRNAs REGULATE THE EPIGENETIC MACHINERY IN
PROSTATE CANCER
As previously observed in lung cancer (Fabbri et al., 2007a) and
hematological malignancies (Garzon et al., 2009), also in PCA
miRNAs have been shown to target key effectors of the epigenetic
machinery (which might act either as OGs or as TSGs themselves),
or they could affect the expression of epigenetically regulated OGs
or TSGs. These two scenarios have been disclosed for miR-101,
regulating EZH2, and miR-449a, regulating HDAC1 (cfr. Table 1).
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Table 1 | Epigenetics and relevant miRNAs in PCA.
miRNA PCA relevant
targets
Role Expression
in PCA
Function Reference
miR-101 EZH2 TSG Down Invasiveness Cao et al. (2010)
miR-449a HDAC1 TSG Down Cell cycle arrest, senescent-like phenotype
and loss of clonogenicity
Noonan et al. (2009)
miR-205 ZEB1/ZEB2** TSG Down EMT Hulf et al. (2011)
miR-200c/
141 cluster
ZEB1/ZEB2 TSG Down EMT Kong et al. (2009)
miR-126 DNMT1** TSG Down N/A Zhao et al. (2011)
miR-145 TNFSF10 TSG Down Apoptosis Zaman et al. (2010)
miR-34
family
SIRT1/CD44 TSG Down Chemoresistance, metastasization, DNA
damage
Lodygin et al. (2008), Rokhlin et al. (2008), Liu
et al. (2011)
miR-21 Multiple targets** OG Down/Up Chemoresistance, androgen-supported
proliferation, castration resistant phenotype
Ribas et al. (2009), Ribas and Lupold (2010),
Shi et al. (2010), Hulf et al. (2011)
miR-615 N/A N/A Up N/A Hulf et al. (2011)
miR-196b N/A TSG Down N/A Hulf et al. (2011)
**Known target not demonstrated in PCA.
PCA, prostate cancer; EZH2, enhancer of zeste homolog 2 (Drosophila); HDAC1, histone deacetylase 1; ZEB1, zinc ﬁnger E-box binding homeobox 1; ZEB2, zinc
ﬁnger E-box binding homeobox 2; DNMT1, DNA methyltransferase 1;TNFSF10, tumor necrosis factor (ligand) superfamily, member 10; SIRT1, sirtuin 1; CD44, cluster
of differentiation 44; N/A, not available; TSG, tumor suppressor gene; OG, oncogene; EMT, epithelial–mesenchymal transition.
Enhancer of zeste homolog 2 is part of multiprotein complex
called polycomb repressive complex 2 (PRC2). These proteins reg-
ulate the tri-methylation of histone H3K27 of several target gene
promoters leading to their epigenetic silencing. EZH2 is consid-
ered anOG since,when overexpressed, it induces cell proliferation,
increases tumor colony formation and increases tumor invasion
both in vitro and in vivo (Varambally et al., 2008). EZH2 is overex-
pressed in hormone refractory, metastatic PCA (Varambally et al.,
2008). MiR-101 expression is frequently reduced in PCA (Lu et al.,
2005; Volinia et al., 2006), and it has been demonstrated that miR-
101 negatively regulates EZH2 expression. Restoration of miR-101
expression in PCA cells attenuates tumor invasiveness. Intrigu-
ingly, both AR and HIF-1-alpha and -beta seem to be able to
inducemiR-101 expression, suggesting thatmiR-101 levels depend
on speciﬁc physiological conditions, and are affected by changes
in the surrounding microenvironment (Cao et al., 2010).
Also HDAC1 has been demonstrated to be overexpressed in
PCA (Patra et al., 2001;Halkidou et al., 2004;Weichert et al., 2008),
and an inverse correlation has been observed between HDAC1 and
miR-449a expression in PCA (Noonan et al., 2009). In the PCA
cell line PC3, miR-449a directly targets HDAC1, and miR-449a
restoration leads to cell cycle arrest, acquisition of a senescent-
like phenotype, and loss of clonogenicity (Noonan et al., 2009).
Part of this observed phenotype could be also mediated by over-
expression of p27 (a known target of HDCA1), upon HDCA1
silencing by miR-449a (Noonan et al., 2009).
Despite some of the miRNAs regulating proteins of the epige-
netic machinery have been identiﬁed, there are still several of these
effectors for which such a regulation can be hypothesized and the
involved miRNAs are being investigated. Therefore, it is likely that
in the near future an increasing number of these miRNAs will
be identiﬁed and will contribute to a better understanding of the
actual function of the targeted epigenetic effectors themselves.
miRNAs ARE EPIGENETICALLY REGULATED IN PROSTATE
CANCER
MicroRNAs undergo the same regulatory mechanisms of any
other PCG, therefore the genes encoding for miRNAs can also
be epigenetically regulated (Fabbri, 2008). In several types of
cancer (including PCA), aberrations of this epigenetic regula-
tion of miRNAs are able to explain, at least in part, some of the
speciﬁc miRNome abnormalities which characterize that speciﬁc
malignant phenotype.
Recently, an integrative approach has been successfully used
to show that the expression of several miRNAs is modiﬁed by
epigenetic modulation in PCA (Hulf et al., 2011). By combin-
ing primary transcription analysis, genome-wide DNA methy-
lation and H3K9Ac marks with miRNA expression, Hulf et al.
(2011) demonstrated that at least three miRNAs are down-
regulated (namely, miR-205, -21, and -196b) and one upregu-
lated (miR-615) by epigenetic mechanisms in PCA. Interestingly,
one of the down-regulated miRNAs, miR-205, is involved in the
epithelial–mesenchymal transition (EMT) process, and together
with another family of miRNAs (namely, the miR-200 family) it
has been extensively studied in several types of cancers, including
PCA (Kong et al., 2009). The miR-200 family includes miR-200a,
miR-200b miR-200c,miR-141, and miR-429. MiRNAs of the miR-
200 family are organized in two clusters, one (encoding for miR-
200b, miR-200a, and miR-429) on chromosome 1, while the other
(encoding for miR-200c and miR-141) is located on chromosome
12. MiR-200 family and miR-205 directly target the E-cadherin
transcriptional repressors ZEB1 and ZEB2, which are implicated
in EMT and affect the formation of metastases, by controlling the
adhesion and invasion processes (Gregory et al., 2008). Recently,
Kong et al. (2009) reported that the miR-200c/miR-141 cluster is
transcribed as a polycistronic RNA, and is silenced by promoter
hypermethylation in several cancer types including PCA. Indeed,
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treatment of PC3 cells with the de-methylating agent 5-aza-2′-
deoxycytidine (5-AZA) induces re-expression of both miRNAs of
the cluster, proving that aberrant epigenetic mechanisms partic-
ipate in the inappropriate repression of the miR-200c/miR-141
cluster, and this could affect the metastatic ability of PCA cells.
Interestingly, the epigenetic regulation of miRNAs appears to
be cancer-type speciﬁc. Indeed, while the expression of miR-196b
is reduced in PCA, miR-196b is upregulated in lymphoblastic
leukemia and gastric cancer cells (Schotte et al., 2010; Tsai et al.,
2010) because of a reduced degree of methylation at the same
CpG island which are hypermethylated in PCA, and are responsi-
ble for miR-196b silencing in PCA. This ﬁnding corroborates the
dual nature or miRNAs, able to act both as OGs and TSGs (Fabbri
et al., 2007b), but also indicates that different strengths of epige-
netic control can be exerted by cancer cells on the same gene, and
the extent of this control depends onother yet not clearly identiﬁed
intracellular factors,whichultimately determinewhether an epige-
netically regulated miRNA is silenced or not, in a cell-type speciﬁc
fashion. Interestingly both miR-615 and miR-196b are located in
CpG islands within the HOX gene clusters, but while the HOXC
cluster host gene has been previously demonstrated to be part
of a long range hypermethylated domain (Coolen et al., 2010),
miR-615, located within this cluster is actually hypomethylated
in PCA. This ﬁnding conﬁrms that miRNA epigenetic regula-
tion is strictly “tailored” and separate for miRNAs and their host
genes.
Also miR-126, frequently down-regulated in PCA and in blad-
der cancer, undergoes epigenetic regulation, since the treatment of
several cancer cell lineswith 5-AZAorPBA (4-phenylbutyric acid),
which is anHDAC inhibitor strongly increasesmiR-126 expression
(Saito et al., 2009). Interestingly, a recent study reported upreg-
ulation of miR-126 in CD4+ T cells of patients with systemic
lupus erythematosus (SLE), and this favors the development of
this disease (Zhao et al., 2011). Moreover, this study identiﬁed
a feed-forward loop in which miR-126 directly targets DNMT1,
leading to a subsequent hypomethylation of miR-126 promoter,
and increased levels of miR-126 (Zhao et al., 2011).
Based on these considerations it would be interesting to investi-
gate whether a “reversed loop”occurs in PCA,where low miR-126,
associated to higher expression of DNMT1, contributes in keeping
the miRNA itself under epigenetic silencing.
Another miRNA frequently down-regulated in PCA with
respect to the normal tissue counterpart is miR-145. Combinatory
treatmentwith 5-AZA and theHDAC inhibitor TCA (trichostatin-
A) increases miR-145 expression, suggesting that also in this case
the silencing is due to epigenetic modulation. Exogenous over-
expression of miR-145 in PC3 cells induces the expression of the
pro-apoptotic geneTNFSF10 leading the cells to apoptosis (Zaman
et al., 2010).
In PCA also miR-193b is silenced by hypermethylation of a
CpG island located about 1 kb upstream of the miRNA locus
(Rauhala et al., 2010). Re-expression of miR-193b in 22Rv1 PCA
cells induced a signiﬁcant tumor growth inhibition, as a result of a
reducednumber of cells in the S-phase of the cell cycle. In addition,
the anchorage independent growth of this same cell line was par-
tially inhibited upon transient expression of miR-193b (Rauhala
et al., 2010).
Another miRNA tightly controlled by promoter methylation in
PCA is miR-34a. Silencing of miR-34a expression is presumably
mediated by CpG methylation of a region located 100–500 base-
pairs upstream of the miR-34a transcription start which includes
a binding site for p53, which transactivates miR-34a transcription
(Raver-Shapira et al., 2007). The different miR-34a expression lev-
els among DU145, PC3, and LNCaP cell lines can only partially
be explained by the promoter methylation status of the miRNA,
therefore it can be hypothesized that the endogenous levels of p53
(different among the different cell lines) contribute to the overall
endogenous expression of this miRNA. Exogenous re-expression
of miR-34a in PC3 cells induces cellular senescence, and per-
manent cell cycle arrest (Lodygin et al., 2008). Finally, miR-34a
has been involved in the control of cancer stem cells popula-
tion balance in PCA. Liu et al. (2011) observed that exogenous
over-expression of miR-34a in CD44 positive PCA cells (that are
considered PCA stem cells) inhibits clonogenic expansion, tumor
regeneration, and metastasis. In contrast, miR-34a silencing in
CD44negative PCA cells, achieved by antagomirs (Krutzfeldt et al.,
2005), promoted tumor development and metastasis, conﬁrming
that miR-34a has an important TSG function in PCA.
Despite miR-21 is generally considered a miRNA which acts as
an OG, its role in PCA is still unclear, given the fact that conﬂict-
ing results have been published. Hulf et al. (2011) demonstrated
a signiﬁcant epigenetic repression of miR-21 in PCA, suggesting a
TSG role for miR-21 in PCA. However, Ribas et al. (2009) found
that over-expression of miR-21 was sufﬁcient to drive androgen-
independent growth in two androgen-dependent PCA cell lines.
Additionally, they observed that miR-21 was enhancing androgen-
supported proliferation of LNCaP cells. Inmousemodels, elevated
levels of miR-21 improved tumor establishment, increased tumor
growth, and induced a castration-resistant phenotype (Ribas and
Lupold, 2010). Overall, these experiments support an OG role
for miR-21, or at least suggest that miR-21 might be implicated
in the switch from hormone-sensitive to hormone-resistant PCA.
Recently, however Folini et al. (2010) showed that miR- 21 knock-
down elicited no change in proliferative or invasive properties
in PCA cells. In the same paper the authors were unable to
conﬁrm a signiﬁcant difference in the expression of miR-21 in
PCA versus normal tissue on a cohort of 36 patients. In sum-
mary, a clear role for miR-21 in prostate carcinogenesis has not
been deﬁned yet, and further studies are warranted to clarify this
issue.
Interestingly, both miR-34 and miR-21 are also involved in
chemoresistance of PCA. MiR-34 downregulation is associated
with the HDAC SIRT1 over-expression, this protein has been
described to be associated with chemoresistance to camptothecin
and cisplatin in PC3 and DU145 cells (Fujita et al., 2008). Artiﬁ-
cial introduction of miR-34a in PC3 cells induces apoptosis and
attenuates chemoresistance to camptothecin through the target-
ing of SIRT1 and probably others cell cycle regulators, previously
described to be targets of miR-34a such as CDK4, CDK6, Cyclin
D1, Cyclin E2, E2F3, and BCL2 (Hermeking, 2007; Fujita et al.,
2008).
The involvement of miR-21 in PCA chemoresistance has been
demonstrated by Shi et al. (2010). They showed that miR-21 is
upregulated in docetaxel resistant PC3 (PC3R) cells compared to
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wild type PC3 cells. This process is mediated by the ability of miR-
21 to target the oncosuppressor gene PDCD4 that is known to
be involved in the sensitivity to other chemotherapic agents like
cisplatin and paclitaxel (Shi et al., 2010).
Several studies have reported that both miR-21 and miR-34a
can act as PCA biomarkers. But while miR-34a has been shown
to be silenced by promoter hypermethylation in PCA, and con-
sequently its expression in the blood of PCA patients is reduced
with respect to non-cancerous patients (Kojima et al., 2010), for
miR-21 there is the conﬂicting evidence of low expression in pri-
mary prostate tumors (due to promoter hypermethylation) but
high expression in the serum of patients with hormone-refractory
PCA (Yaman Agaoglu et al., 2011; Zhang et al., 2011). Again, these
ﬁndings highlights the need to better understand what is the role
of miR-21 in prostate carcinogenesis and in particular how its
epigenetic regulation affects the shift toward hormone-refractory
PCA.
EPIGENETICS OF THE ANDROGEN RECEPTOR: ROLE OF
miRNAs
Androgen receptor is the main actor in the development and pro-
gression of PCA and controlling its activity represents one of the
most important goals in the clinical management of PCA. Despite
its relevance for PCA, the mechanisms that regulate the expression
of this protein remain poorly understood. While in some cases
AR is not functional because of genetic mutations, in up to 40%
of PCA patients (and in the DU145 cell line as well) it has been
found to be silenced by promoter hypermethylation (Jarrard et al.,
1998; Kinoshita et al., 2000; Nakayama et al., 2000; Sasaki et al.,
2002; Yamanaka et al., 2003; Reibenwein et al., 2007), revealing a
remarkable role of epigenetics in AR expression regulation. Other
described mechanisms of AR aberrant expression and function
include genetic ampliﬁcation, generation of ligand-independent
receptor variants, downregulation of AR repressors, persistence of
intratumoral androgens, or upregulation of signals that activate
AR also in absence of androgens (for a complete review see Shen
and Abate-Shen, 2010).
In PCA, AR can function in two opposite directions: on one
side, AR signaling is crucial for prostate and PCA cell survival
(Shen and Abate-Shen, 2010), however its activation can also limit
cell proliferation and mediate apoptotic induction under spe-
ciﬁc circumstances (Shen and Abate-Shen, 2010). For example,
under genotoxic stress AR is fundamental for p53 activation and
for the subsequent induction of apoptosis (Heinlein and Chang,
2004; Rokhlin et al., 2008). Since it has been estimated that miR-
NAs can regulate the expression of about 30% of the human
genes (Lewis et al., 2005), there has been interest in investigat-
ing whether miRNAs can regulate the expression of AR. Despite
a large number of miRNAs has been shown to be able to regu-
late AR expression (Sikand et al., 2010; Ostling et al., 2011), there
is a substantial gap between the basic research ﬁndings and the
expression of these miRNAs in clinical samples, raising the ques-
tion of the relevance of these results for translational research
purposes.
Conversely, it can be expected that reduced expression of AR-
targeting miRNAs is responsible for AR increased expression.
Recently, Ostling et al. (2011) demonstrated that AR-3′-UTR is
much longer than contemplated by the most frequently used
miRNA target prediction programs. In particular, the authors
demonstrated that at least 71 miRNAs affect AR expression in
PCA cell lines, and they conﬁrmed that 13 of them directly bind
to and regulate the 6-kb extended 3′-UTR of AR. Among them,
miR-34a and miR-34c are particularly interesting, since, as we pre-
viously described, they are epigenetically regulated in PCA, and
could represent the missing link between epigenetics–miRNAs
and AR regulation in PCA (Figure 1). In 2008, Rokhlin et al.
(2008) demonstrated that miR-34a and miR-34c are involved in
the apoptotic induction after p53 activation in PCA cells, and
that pro-apoptotic functions of DNA damage-induced p53 and
miR-34s are dependent upon AR activation. Therefore, a central
role of the epigenetically regulated miR-34 family members in the
physiology of AR in PCA can be claimed (Figure 1).
In addition to miR-34s, other miRNAs have been reported
to be controlled by AR. Narayanan et al. (2010) demonstrated
that by blocking miRNAs maturation most of the functions of
AR are also blocked. Speciﬁcally, they observed that the silenc-
ing of DICER (a key enzyme in miRNA biogenesis) prevents
DHT (dihydrotestosterone)-induced PSA production. They also
demonstrated that by silencing DICER, DHT activation of AR
results inupregulationof NCOR1andNCOR2, twowell character-
ized AR co-repressors, a mechanism bona ﬁde miRNA-mediated,
despite the actual miRNAs involved have not been identiﬁed in
this study (Figure 1). Also miR-21 has been demonstrated to be
directly transactivated by AR, through an AR binding site on the
miRNA promoter (Ribas et al., 2009). These ﬁndings corroborate
FIGURE 1 | MicroRNAs and Epigenetic Regulation of the Androgen
Receptor in Prostate Cancer. MiR-34 family has been shown to directly
target the Androgen Receptor (AR) in Prostate Cancer (PCA). Also, miR-34
family can be transactivated by AR, leading to a feedback regulatory loop,
and to p53-mediated pro-apoptotic effects. Promoter hypermethylation has
been described as a main epigenetic regulatory mechanism for miR-34
family expression in PCA. Also miR-21 is transactivated by AR, but its
over-expression promotes an oncogenic signaling. Finally, activation of AR
has been shown to induce yet not-better identiﬁed miRNAs, which target
NCOR1 (nuclear receptor corepressor 1) and NCOR2 (nuclear receptor
corepressor 2), co-repressors of AR.
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the need for a deeper investigation on the role of miR-21 in the
acquisition of a hormone-resistant PCA phenotype. Finally, it has
been demonstrated that a group of ﬁve miRNAs (namely miR-
141, -494, 29a, -29b, and -29c) which directly target effectors of
the epigenetic machinery, are also induced by DHT stimulation in
VCaP andAR-expressing LNCaP cells (Waltering et al., 2010). This
ﬁnding casts a new light on the interaction betweenAR function in
PCA and miRNA controlling key enzymes ruling gene epigenetic
regulation.
CONCLUSION
The genetics of PCA is complex and only partially understood.
In recent years, the discovery that a speciﬁc subgroup of ncRNAs,
called miRNAs, is implicated in the pathogenesis and dissemina-
tion of this cancer has shown that the molecular biology of PCA
is more complex than initially thought. Moreover, the ﬁnding that
epigenetic mechanisms are responsible for some of the aberra-
tions of the miRNome which are hallmarks of PCA and/or its
resistance to drugs has introduced a new layer of complexity to
the picture. Despite this apparent intricacy, an accurate dissection
of all the molecular mechanisms responsible for the pathogene-
sis and clinical behavior of this disease is the absolutely necessary
background to understand which are the best molecular targets
for the treatment of PCA. Undoubtedly, for some aspects, we are
still at the dawn of our comprehension. Unconﬁrmed data and, in
some cases, even conﬂicting results witness the need for a deeper
insight into the intertwined mechanisms that drive cells to develop
a malignant phenotype. Therefore (and almost paradoxically), the
discovery of an increased complex interaction betweenwell known
OGs and TSGs, epigenetics and new characters like the miRNAs,
ends up being one of the fastest ways to identify new promis-
ing therapeutic targets, especially (yet not exclusively) for those
patients who still have an uncurable PCA.
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